-
Mashup Score: 38Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma - 2 month(s) ago
Key Points. SOC cilta-cel in RRMM results in deep and durable response despite over half the patients not meeting CARTITUDE-1 eligibility criteria.Close su
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 18Public Health Sex Party Hypocrisy - 2 month(s) ago
The VPZD Show · Episode
Source: open.spotify.comCategories: General Medicine News, Hem/OncsTweet-
This episode was hilarious. Got me through an hour run. @VPrasadMDMPH https://t.co/6H8eCAX4NV
-
-
Mashup Score: 62eClinPath | A Resource for Veterinary Clinical Pathology - 3 month(s) ago
Welcome to eClinPath, an online textbook on Veterinary Clinical Pathology The goal of this site is to be an educational resource on veterinary clinical pathology – an “on-line” textbook as it were. We hope this will be a valuable resource, as are the several available paper textbooks on this discipline. We continually strive to update and […]
Source: eclinpath.comCategories: General Medicine News, Hem/OncsTweet-
Happy Halloween! Image from https://t.co/ZF5JMiGmtD https://t.co/6GBMmq0XVu
-
-
Mashup Score: 62eClinPath | A Resource for Veterinary Clinical Pathology - 3 month(s) ago
Welcome to eClinPath, an online textbook on Veterinary Clinical Pathology The goal of this site is to be an educational resource on veterinary clinical pathology – an “on-line” textbook as it were. We hope this will be a valuable resource, as are the several available paper textbooks on this discipline. We continually strive to update and […]
Source: eclinpath.comCategories: General Medicine News, Hem/OncsTweet-
Happy Halloween! Image from https://t.co/ZF5JMiGmtD https://t.co/6GBMmq0XVu
-
-
Mashup Score: 227News & Notes: Fall 2024 - 3 month(s) ago
The Longitudinal Knowledge Assessment (LKA®): Enrollment now open in 17 specialties; How does ABIM create assessment questions?; Has your practice changed?; You can deactivate your certificate in that discipline; Study finds new Milestones Rating System reduces but does not eliminate bias in residency knowledge ratings; How the physician community informs ABIM’s programs; Research Roundup
Source: blog.abim.orgCategories: General Medicine News, Hem/OncsTweet-
ABIM has eliminated 2 year MOC points! In case not everyone is an avid reader of the ABIM blog I provided a link Hopefully next on their list of elimination is LKA and 10 year recertification. @doctorwes @VincentRK @chadinabhan https://t.co/E746alDmfL https://t.co/Y9LB2Z0D3g
-
-
Mashup Score: 9Ain't It A Shame (Demo) - 3 month(s) ago
Provided to YouTube by Universal Music GroupAin’t It A Shame (Demo) · NirvanaWith The Lights Out – Box Set℗ 2004 Sub Pop RecordsReleased on: 2011-01-01Produc…
Source: www.youtube.comCategories: General Medicine News, Hem/OncsTweet-
Nirvana playing a blues song They rocked it https://t.co/5iO9JObxSC
-
-
Mashup Score: 75
The goal of this research study is to test if ciltacabtagene autoleucel (cilta-cel) is safe and effective in treating participants with high-risk, smoldering myeloma. The names of the treatment interventions used in this study are: – Cilta-cel (or chimeric antigen receptor T cells) – Cyclophosphamide (a lymphodepleting chemotherapy) – Fludarabine (a lymphodepleting chemotherapy)
Source: www.dana-farber.orgCategories: General Medicine News, Hem/OncsTweet-
The US medical system in all its glory! You can you be completely healthy, get a lab test checked you never needed, and end up receiving a toxic million dollar therapy with risks of secondary cancers and long term neurologic side effects. CAR-PRISM https://t.co/OGkPp1s431
-
-
Mashup Score: 73
The goal of this research study is to test if ciltacabtagene autoleucel (cilta-cel) is safe and effective in treating participants with high-risk, smoldering myeloma. The names of the treatment interventions used in this study are: – Cilta-cel (or chimeric antigen receptor T cells) – Cyclophosphamide (a lymphodepleting chemotherapy) – Fludarabine (a lymphodepleting chemotherapy)
Source: www.dana-farber.orgCategories: General Medicine News, Hem/OncsTweet-
The US medical system in all its glory! You can you be completely healthy, get a lab test checked you never needed, and end up receiving a toxic million dollar therapy with risks of secondary cancers and long term neurologic side effects. CAR-PRISM https://t.co/OGkPp1s431
-
-
Mashup Score: 36Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma - 3 month(s) ago
Key Points. SOC cilta-cel in RRMM results in deep and durable response despite over half the patients not meeting CARTITUDE-1 eligibility criteria.Close su
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
Cilta cel in real world 10% non relapse mortality with only 13 month follow up. Sounds like an excellent drug for smoldering myeloma and frontline Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma https://t.co/x1m8kiywwv
-
-
Mashup Score: 2ClinicalTrials.gov - 4 month(s) ago
Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Source: clinicaltrials.govCategories: General Medicine News, Hem/OncsTweet-
@VincentRK @MayoMyeloma Do you still recommend enrolling in the ADVANCE study? https://t.co/AJpsboFkFx
-
Cilta cel in real world 10% non relapse mortality with only 13 month follow up. Sounds like an excellent drug for smoldering myeloma and frontline Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma https://t.co/x1m8kiywwv